摘要
目的探讨恶性血液病患者血清乳酸脱氢酶(LDH)水平变化情况。方法选择2015—2018年在我院及咸阳市中心医院诊治的56例恶性血液病患者,其中急性白血病(AL)19例,多发性骨髓瘤(MM)29例,非霍奇金淋巴瘤(NHL)8例。以同一时期60例健康体检者作为对照组。采用全自动生化检测仪测定患者初诊时、第一次完全缓解时(CR1)及复发时的LDH水平,并与对照组进行比较。结果AL、MM和NHL患者初诊时的LDH水平均明显高于对照组(P<0.05);AL、MM和NHL患者CR1时的LDH水平与对照组比较,差异无统计学意义(P>0.05);恶性血液病患者初诊时及复发时的LDH水平明显高于CR1时及对照组,差异具有统计学意义(P<0.05)。结论血清LDH可作为反映机体肿瘤负荷的一项重要指标,可判断恶性血液病患者的疗效和预后。
Objective To investigate the changes of levels of serum lactate dehydrogenase(LDH)in patients with hematological malignancies.Methods From 2015 to 2018,56 patients with hematological malignancies diagnosed and treated in our hospital and Xianyang central hospital were selected,including 19 patients with acute leukemia(AL),29 patients with multiple myeloma(MM)and 8 patients with non Hodgkin's lymphoma(NHL).Sixty healthy physical examination persons in the same period were selected as the control group.The LDH levels of patients at the initial diagnosis,the first complete remission(CR1)and recurrence were measured by automatic biochemical detector,and were compared with the control group.Results The LDH levels of AL,MM and NHL patients at the initial diagnosis were significantly higher than that of the control group(P<0.05).There were no significant differences in LDH levels between AL,MM and NHL patients at CR1 and in the control group(P<0.05).The levels of LDH in patients with hematological malignancies at the initial diagnosis and recurrence were significantly higher than those at CR1 and in the control group,
作者
黄灵娟
贾永廉
李瑞花
贺文赟
HUANG Ling-juan;JIA Yong-lian;LI Rui-hua;HE Wen-yun(General Medicine Department,the First Affiliated Hospital of Xi'an Medical University,Xi'an 710077;General Medicine Department,Jingbian County People's Hospital,Yulin 718500;Hematology Department,Xianyang Central Hospital,Xianyang 712000;Xi'an Jiaotong University Health Science Center,Xi'an 710061,China)
出处
《临床医学研究与实践》
2020年第1期47-48,共2页
Clinical Research and Practice
基金
西安市科技局科技计划项目[No.201805095YX3SF29(8)]
关键词
乳酸脱氢酶
恶性血液病
急性白血病
多发性骨髓瘤
lactate dehydrogenase
hematological malignancies
acute leukemia
multiple myeloma
